(Q37737198)

22 August 2017

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges (English)

1 reference

22 August 2017

Sumithra J Mandrekar

1

1 reference

22 August 2017

Rui Qin

series ordinal

2

1 reference

22 August 2017

Daniel J Sargent

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

Statistics in Medicine

1 reference

22 August 2017

29

1 reference

22 August 2017

10

1 reference

22 August 2017

1077-1083

1 reference

Designs for single- or multiple-agent phase I trials

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Monoclonal antibodies as therapeutic agents for cancer

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Cancer phase I clinical trials: efficient dose escalation with overdose control.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Design and analysis of phase I clinical trials

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Recent developments in adaptive designs for Phase I/II dose-finding studies

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Translation of innovative designs into phase I trials.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

An adaptive dose-finding design incorporating both toxicity and efficacy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Dose-finding based on efficacy-toxicity trade-offs

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Some practical improvements in the continual reassessment method for phase I studies.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931331

Dose-finding designs for HIV studies

1 September 2018

1 reference

12 December 2020

A new dose-finding design for bivariate outcomes

1 reference

12 December 2020

New look at an old costimulator

1 reference

12 December 2020

Two-dimensional dose finding in discrete dose space

1 reference

12 December 2020

Dose escalation trial designs based on a molecularly targeted endpoint

1 reference

12 December 2020

Identifiers

DOI

10.1002/SIM.3706

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

20419760

1 reference